Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies
Contact us

News Archives

2012

Filter by date

5 Mar 2012

Phosphate Therapeutics, co-owned and resourced by Shield Therapeutics, acquires licence to and €10.5m funding for Phase 2-ready phosphate binder for treatment of hyperphosphataemia

Shield Therapeutics (Shield), the independent specialty mineral-medicines pharmaceutical company, today notes that Phosphate Therapeutics, a company co-owned and resourced by Shield Therapeutics and its shareholders,…

5 Mar 2012

Phosphate Therapeutics acquires novel phosphate binder (PT20) from the Medical Research Council and secures development funding from Inventages Venture Capital for Compound’s Phase II Development

Phosphate Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that it has signed an exclusive agreement with…

4 Jan 2012

Shield Therapeutics to Present at Biotech Showcase™ 2012

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet…